Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02626338 · ClinicalTrials.gov registry record · Phase 1
Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML
A Phase 1 study, sponsored by Arog Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT02626338 is a Phase 1 study that has completed, run by Arog Pharmaceuticals. The registered enrollment target is 16 participants.
The verdict
NCT02626338, a Phase 1 study, has completed, sponsored by Arog Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The proposed study is designed to combine crenolanib with standard salvage chemotherapy to treat patients with R/R AML irrespective the FLT3 status.
Interventions
- DRUG Fludarabine
- DRUG Etoposide
- DRUG Cytarabine
- DRUG Mitoxantrone
- DRUG Crenolanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2016-02 |
| Est. Completion | 2018-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02626338
The ClinicalTrials.gov registry entry for NCT02626338 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arog Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Fludarabine is the first listed.
NCT02626338 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02626338 about?
NCT02626338 is a clinical study titled "Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML". The proposed study is designed to combine crenolanib with standard salvage chemotherapy to treat patients with R/R AML irrespective the FLT3 status.
What is the current status of trial NCT02626338?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2016-02. Estimated completion is 2018-02.
What interventions are being tested in trial NCT02626338?
The interventions under investigation include: Fludarabine (DRUG), Etoposide (DRUG), Cytarabine (DRUG), Mitoxantrone (DRUG), Crenolanib (DRUG).
Who is sponsoring clinical trial NCT02626338?
This trial is sponsored by Arog Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.